Literature DB >> 15349870

Novel PINK1 mutations in early-onset parkinsonism.

Yasuko Hatano1, Yuanzhe Li, Kenichi Sato, Shuichi Asakawa, Yasuhiro Yamamura, Hiroyuki Tomiyama, Hiroyo Yoshino, Masato Asahina, Susumu Kobayashi, Sharon Hassin-Baer, Chin-Song Lu, Arlene R Ng, Raymond L Rosales, Nobuyoshi Shimizu, Tatsushi Toda, Yoshikuni Mizuno, Nobutaka Hattori.   

Abstract

PINK1 was recently found to be associated with PARK6 as the causative gene. We performed mutation analysis in eight inbred families whose haplotypes link to the PARK6 region. We identified six pathogenic mutations (R246X, H271Q, E417G, L347P, and Q239X/R492X) in six unrelated families. All sites of mutations were novel, suggesting that PINK1 may be the second most common causative gene next to parkin in parkinsonism with the recessive mode of inheritance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349870     DOI: 10.1002/ana.20251

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  77 in total

1.  Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations.

Authors:  Susanne Steinlechner; Jessica Stahlberg; Birgit Völkel; Ana Djarmati; Johann Hagenah; Anja Hiller; Katja Hedrich; Inke König; Christine Klein; Rebekka Lencer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-03       Impact factor: 10.154

2.  PINK1 mutation heterozygosity and the risk of Parkinson's disease.

Authors:  M Toft; R Myhre; L Pielsticker; L R White; J O Aasly; M J Farrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

3.  Congenital disease SNPs target lineage specific structural elements in protein kinases.

Authors:  Ali Torkamani; Natarajan Kannan; Susan S Taylor; Nicholas J Schork
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-25       Impact factor: 11.205

Review 4.  Progress in the pathogenesis and genetics of Parkinson's disease.

Authors:  Yoshikuni Mizuno; Nobutaka Hattori; Shin-Ichiro Kubo; Shigeto Sato; Kenya Nishioka; Taku Hatano; Hiroyuki Tomiyama; Manabu Funayama; Yutaka Machida; Hideki Mochizuki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-27       Impact factor: 6.237

5.  Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism.

Authors:  Ji-feng Guo; Xue-wei Zhang; Li-luo Nie; Hai-nan Zhang; Bin Liao; Jing Li; Lei Wang; Xin-xiang Yan; Bei-sha Tang
Journal:  J Neurol       Date:  2010-02-10       Impact factor: 4.849

6.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

7.  HILAQ: A Novel Strategy for Newly Synthesized Protein Quantification.

Authors:  Yuanhui Ma; Daniel B McClatchy; Salim Barkallah; William W Wood; John R Yates
Journal:  J Proteome Res       Date:  2017-05-03       Impact factor: 4.466

8.  Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation.

Authors:  Jügen Prestel; Klaus Gempel; Till-Karsten Hauser; Katherine Schweitzer; Holger Prokisch; Uwe Ahting; Dirk Freudenstein; Eva Bueltmann; Thomas Naegele; Daniela Berg; Thomas Klopstock; Thomas Gasser
Journal:  J Neurol       Date:  2008-02-21       Impact factor: 4.849

9.  PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease.

Authors:  Wencheng Liu; Cristofol Vives-Bauza; Rebeca Acín-Peréz-; Ai Yamamoto; Yingcai Tan; Yanping Li; Jordi Magrané; Mihaela A Stavarache; Sebastian Shaffer; Simon Chang; Michael G Kaplitt; Xin-Yun Huang; M Flint Beal; Giovanni Manfredi; Chenjian Li
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.